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Objective To deﬁne the bronchodilator response (BDR) cutoff point that best identiﬁed asthma to determine the frequency
of abnormal spirometry results across severity.
Study design Controller naïve children were evaluated with clinical criteria alone to establish a diagnosis of asthma and
severity classiﬁcation, then compared with the BDR, which was calculated as the percent change from the initial forced
expiratory volume in 1 second. Receiver operator characteristic analysis determined the cutoff point for asthma diagnosis that
gave the best combination of sensitivity and speciﬁcity.
Results Children with asthma (n  346) and 51 children without asthma, aged 4 to 17 years, who met entry criteria for
spirometry were identiﬁed. The mean BDR in asthmatics was 8.6% (95% CI, 7.5-9.8), compared with 2.2% (95% CI, 0.2-4.3)
for non-asthmatics (P < .001). A BDR >9% best differentiated these populations with a sensitivity rate of 42.5% and a
speciﬁcity rate of 86.3%. Abnormal spirometry results, deﬁned as a BDR >9%, a forced expiratory volume in 1 second <80%
predicted, or both, ranged from 44.4% for mild intermittent bronchial asthma to 57.0% for severe persistent bronchial asthma.
Conclusion Spirometric criteria that include BDR can potentially identify children who have clinically mild asthma and
might beneﬁt from controller therapy. (J Pediatr 2007;151:457-62)
A
ccording to the National Asthma Education and Prevention Program (NAEPP) guidelines spirometry, including
baseline forced expiratory volume in 1 second (FEV1) and the bronchodilator response (BDR) to short acting beta
agonists (SABA), should be undertaken in children as objective measures to establish the diagnosis and severity of
bronchial asthma (BA).
1 Spirometry is thought to be necessary because physician evaluation on a clinical basis alone may not
adequately detect airway obstruction
2 and reliance on patient or parent-reported symptoms may not provide an accurate
diagnosis of BA.
3 Spirometry use in a pediatric clinic setting can lead to important changes in pharmacotherapy that were not
initially indicated with clinical evaluation.
4,5 However, serious questions have been raised about its value to pediatricians as a
practical in-ofﬁce tool.
6 In addition, baseline FEV1, the “gold standard” for evaluating
airway obstruction,
1 is usually in the reference range (80% predicted) in children,
regardless of BA severity,
7 thus limiting its value for diagnosis and treatment strategy.
Because of this limitation, several other objective measures have been suggested for
diagnosis and treatment in children, including the BDR,
8-13 which reﬂects not only
airway reversibility, central to diagnosis, but also may represent a surrogate marker of
airway inﬂammation.
11-14 The current deﬁnition of a positive BDR (12% reversibility
and 200 mL increase in initial FEV1) after SABA
15 has been established primarily in
adults. A recent report suggested that a 9% BDR cutoff point best distinguishes children
with asthma from children without asthma.
10
The purpose of this retrospective, observational study was to determine the BDR
cutoff point that best differentiates children with asthma from children without asthma
and establish the frequency of abnormal baseline FEV1 and BDR values across symptom-
based asthma severity in a cohort of children who are controller naïve.
BA Bronchial asthma
BDR Bronchodilator response
FEV1 Forced expiratory volume in 1 second
FVC Forced vital capacity
MI Mild intermittent asthma
MIP Mild persistent asthma
MOP Moderate persistent asthma
NAEPP National Asthma Education Prevention
Program
ROC Receiver operator characteristics
SABA Short acting bronchodilator
SP Severe persistent asthma
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457METHODS
Patient Population
Children participating in a school-based, low-income
asthma mobile van program, the Breathmobile (S.C. Johnson
and Son, Inc., Racine, WI),
16 were recruited from school
nurses, community public health clinics, response to ﬂyers,
and an asthma screening questionnaire. Criteria for the diag-
nosis of asthma made by the asthma specialist included a
history of recurrent coughing, wheezing, or shortness of
breath at rest or with exercise, symptomatic improvement
after bronchodilator use, and exclusion of other diagnoses.
1
Patients who did not have these characteristics were classiﬁed
as non-asthmatic control subjects. This distinction was made
solely on clinical grounds without the results of spirometry.
Asthma severity was evaluated by using daytime/night-
time symptom frequency criteria as described in the NAEPP
guidelines.
1 Patients not receiving controller medication in
the 6 to 8 weeks before the initial evaluation were considered
controller naïve. The patients were not excluded from the
BDR evaluation on the basis of earlier albuterol use or recent
upper respiratory tract infection.
Institutional review was waived by Children’s Hospital
of Orange County’s institutional review board because data
acquisition analysis was not directly linked to individual pa-
tient identities.
Spirometry
Pulmonary function testing was attempted in children
aged 4 years in the standing position. Spirometric results
were included in the analysis only when the child completed
at least 3 baseline forced vital capacity (FVC) maneuvers that
met American Thoracic Society criteria in a maximum of 6
attempts and was able to successfully complete post-bron-
chodilator (BD) spirometry.
15 An observation of the ﬂow
expiratory curve was made to ensure that the forced expiratory
time (FET) was 1 second in all age groups, particularly in
the 4- to 7-year-old population.
17 In addition, the software
had a computer bell that sounded when the curve reached
completion. The best spirometric measures of at least 3 at-
tempts were recorded for analysis, including FVC, FEV1,
FEV1/FVC ratio, and the forced expiratory ﬂow (FEF25-75)
predicted. Post-BD spirometry was evaluated 10 minutes after
administrating 2 puffs (180 mcg) from an albuterol metered dose
inhaler with a spacer, or nebulized Albuterol pre-mix (.083%) at
a dose equivalent to 2.5 mg of albuterol. The latter was used in
younger patients or when the metered dose inhaler technique
was not successful. Completed and acceptable spirometric
measures were compared with the Knudson Intermountain
Thoracic Society normal predicted values and adjusted for
ethnic values on the basis of a parent report of ethnicity or
race.
18 Spirometry was performed by a nurse trained by the
asthma specialist. The spirometric equipment was purchased
from Creative Biometrics International (WIN DX, version
1.00.54). This instrument gives visual incentives to either
blow out candles or blow up balloons. It was calibrated on a
daily basis. Because FEV1 is the guideline “gold standard” for
assessing airway obstruction,
1 it was the only baseline measure
used in this analysis. The BDR was calculated as follows
15:
FEV1 mls post-BD
FEV1 mls pre-BD/FEV1 pre-BD FEV1 mls100%.
Statistical Analysis
Analysis of variance was conducted to assess signiﬁ-
cance of differences in mean FEV1% predicted pre- and post-
BD and BDR across asthma diagnosis and severity groups.
Multivariate analysis of varaince enabled examination of
potential confounding effects of age, sex, ethnicity, and
height on the relationship between severity and spirometric
measures. The receiver operator characteristic (ROC)
curve evaluated the diagnostic accuracy of the BDR ex-
pression to identify asthma.
19 Sensitivity, speciﬁcity, and
positive and negative predictive values on the basis of single
cutoff values for the continuous BDR expression to positively
identify asthma were calculated across a range of optimal
points. Chi-square tests evaluated signiﬁcance of association
between abnormal spirometry results and asthma diagnosis
and level of symptom severity in asthmatic patients.
RESULTS
Demographic characteristics of both the asthmatic and
non-asthmatic populations that successfully completed both
pre- and post-BD maneuvers are shown in Table I. There
were 346 children with asthma and 51 children without
asthma, with an age range of 4.5 to 17.8 years and 4.2 to 15.5
years, respectively. The mean height for each group was
similar. None of the group differences was statistically signif-
icant. Evaluation of symptom-based classiﬁcation of asthma
severity
1 revealed that 34% of children had mild intermittent
(MI) disease, 12% of children had mild persistent (MIP)
disease, 26% of children had moderate persistent (MOP)
disease, and 27% of children had severe persistent (SP) disease
(Table I). The 51 patients without asthma consisted primarily
of children with recurrent upper respiratory tract problems,
including allergic rhinitis, adeno-tonsillitis, or recurrent si-
nusitis.
Signiﬁcant differences in the unadjusted (univariate)
and adjusted (multivariate) models were observed in the pre-
BD FEV1 of 91% predicted for the children with asthma and
97% predicted FEV1 for the children without asthma, (P 
.005, P .003, respectively; Table II). Comparing children
without asthma with children with asthma of different sever-
ity, statistical signiﬁcance was seen starting with those with
MIP (P  .037). On average, younger children (4-7 years old)
and older children (10 years old) had higher pre- and post-
bronchodilator values compared with children 8 to 10 years
old across severity categories. There were no signiﬁcant dif-
ferences in the post-BD FEV1 between the non-asthmatic
group and asthmatic group regardless of severity.
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asthma diagnosis
Post-albuterol response measured Signiﬁcance of asthma
Dx group difference No asthma (n  51) Asthma (n  346)
Age, mean (95% CI) 9.0 years (8-10)* 9.8 years (9,10)* t  1.68, P  .094
4-7 years 19 (37%) 115 (33%)
8-10 22 (43%) 113 (33%)
10 10 (20%) 118 (34%)
Sex 
2
(1 df)  0.11, P  .745
Male 31 (61%) 202 (58%)
Female 20 (39%) 144 (42%)
Ethnicity 
2
(1 df)  0.66, P  .417
Hispanic 45 (88%) 290 (84%)
Other 6 (12%) 56 (16%)
Height, mean (95% CI) 134 cm (129-138)* 138 cm (135-140)* t  –1.27, P  .203
Symptom severity
Mild intermittent 119 (34%)
Mild persistent 42 (12%)
Moderate persistent 91 (26%)
Severe persistent 94 (27%)
DX, Diagnosis.
*95% CI.
Table II. Examination of asthma diagnosis and symptom severity group differences in average
FEV1%-predicted
Asthma Dx and symptom
severity Patients, n (%)
FEV1% pre pred,
mean (95% CI)
FEV1% post-
bronchodilator,
mean (95% CI)
BDR- FEV1%
initial,
mean (95% CI)
No asthma group 51 (12.8%) 97 (93-100) 99 (95, 102) 2.2% (0.2, 4.3)
Asthma Dx—overall 346 (87.2%) 91 (89-92) 99 (97, 100) 8.6% (7.5, 9.8)
Mild Intermittent 119 (30.0%) 93 (91-96) 100 (97, 103) 7.6% (5.8, 9.5)
Mild Persistent 42 (10.6%) 91 (87-95) 98 (95, 102) 7.3% (4.2, 10.4)
Moderate Persistent 91 (22.9%) 90 (87-94) 99 (95, 102) 9.1% (6.9, 11.3)
Severe Persistent 94 (23.7%) 87 (84-91) 97 (94, 101) 10.1% (7.6, 12.6)
ANOVA
Asthma Dx and symptom
severity
Group differences Unadjusted model* F  3.8 (P  .005) F  0.4 (P  .796) F  5.2 (P  .001)
Adjusted model† F  4.0 (P  .003) F  0.4 (P  .824) F  5.2 (P  .001)
Contrast comparisons (adjusted
models)
No asthma versus asthma Dx (P  .003) (P  .779) (P  .001)
No asthma versus
intermittent symptoms
(P  .107) (P  .818) (P  .002)
No asthma versus mild
persistent symptoms
(P  .037) (P  .701) (P  .019)
No asthma versus moderate
persistent symptoms
(P  .014) (P  .957) (P  .001)
No asthma versus severe
persistent symptoms
(P  .001) (P  .492) (P  .001)
Pred, Predicted.
change; analysis performed after removal of outliers for BDR (7 values 70.0%).
BDR-% change from initial FEV1mls: no factors signiﬁcant in model that controls for asthma Dx and symptom severity.
*Variable Coding: no asthma, intermittent symptoms, mild persistent symptoms, moderate persistent symptoms, and severe persistent symptoms.
†Additional factors considered in adjusted (multivariate) models: age (4-7, 8-10, 10 years), ethnicity (Hispanic and other), sex, and height (cm). Signiﬁcance of asthma diagnosis
and symptom severity variable in each model adjusted for these signiﬁcant demographic characteristics, described by outcome:
FEV1% pre: (Age, P  .001).
FEV1% post: (Age, P  .003).
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differentiation between the asthmatic group and non-asth-
matic group (P  .001) than pre-BD FEV1 (Table II), with
statistical signiﬁcance noted even in the MI disease group
(P  .002). The BDR in the non-asthmatic group showed a
mean of 2.2% (95% CI, 0.2-4.3) response compared with
8.6% (95% CI, 7.5-9.8) in the asthma group (P  .001). The
range seen was 7.6% (95% CI, 5.8-9.5) for MI asthma to
10.1% (95% CI, 7.6-12.6) in the SP group. In the multivar-
iate analysis, the only variable that was signiﬁcant was severity
(P  .001). Age, ethnicity, sex, and height did not impact the
positive relationship of asthma diagnosis and increased sever-
ity to BDR. Some children, however, were unable to perform
pre- and post-BD responses and were not included in this
analysis. Less than 50% of children 6 years old were able to
adequately perform both responses, 74% of children aged 6 to
7 years, 80% of children aged 8 to 10 years old, and 96% of
children 10 years old.
ROC analysis to identify asthma by BDR was per-
formed (Figure 1; available at www.jpeds.com). The area
under the curve was 0.674 (P  .001). The cutoff points
closest to the left-hand border and the top border of the ROC
space that provide the best possible tradeoff between sensi-
tivity and speciﬁcity are presented below the plot. A cutoff
point 9% offered optimal balance with a sensitivity rate of
42.5% and a speciﬁcity rate of 86.3%, a positive predictive
value of 95.5%, and a negative predictive value of 18.1%.
Applying a cutoff point 12% gave a better speciﬁcity rate of
94.1%, but the sensitivity rate was substantially reduced to
only 30.4%, the positive predictive value was 97.2%, and the
negative predictive value was 16.7%. The percentage of those
with 9% BDR increased with BA severity regardless of
baseline FEV1 (data not shown).
In Figure 2A, we compare the percentage of abnormal
spirometry results, either baseline FEV1 80%, BDR 9%,
or both, between the asthmatic group and the non-asthmatic
group and across severity. The percentage of children with a
FEV1 80% either alone or in combination with BDR 9%
ranged from 19.7% to 24.7% in children with MI BA to
children with SP BA (P  .704). In the non-asthmatic group,
the FEV1 80% alone was 7.8%, and none had the combi-
nation criteria. In contrast, the BDR 9%, either alone or in
combination with FEV1 80%, ranged from 13.7% in the
non-BA group to 51.1% in the group with SP BA (P  .002).
Using either/or criteria, children with asthma were signiﬁ-
cantly more likely to have abnormal spirometry results
(49.3%, compared with 21.5% of the children without
asthma; P  .001). Although non-signiﬁcant, the percent-
age of abnormal spirometry results increased with severity,
reaching 57.1% in the SP group (P  .323). However,
44.4% of children with MI BA also had abnormal spirom-
etry results. The BDR 9% contributed to most of the
abnormal ﬁndings across severity, most of which were seen
when the baseline FEV1 was 80% (normal). In Figure
2B, with the BDR cutoff point 12%, we observed the
same pattern, but abnormal spirometry results were found
less often in the non-BA group (13.7% compared with
21.5%), reﬂecting greater BDR speciﬁcity, with decreased
sensitivity particularly noted in the MI group in which
abnormal spirometry results were seen in 34.2%, compared
with 44.4%. This was mainly caused by decreased positive
BDR from 35.9% to 21.3% comparing the 9% with the
12% cutoff point criteria.
DISCUSSION
We have shown in a controller naïve, inner city pedi-
atric population that those in whom asthma is diagnosed on
a clinical basis by an asthma specialist had signiﬁcantly greater
mean BDR, even at the mildest level, compared with those
who were deemed non-asthmatic, regardless of age, sex,
height, or ethnicity. This distinction was clearly better than
that shown by means of baseline FEV1 (Table II; Figure 2A
and B). Several reports have shown that the mean BDR can
differentiate BA from non-BA by using impulse oscillom-
Figure 2. A, Percent of patients in each category deﬁned by baseline FEV1 80% and BDR 9% described by asthma diagnosis status and symptom
severity. FEV1 80% BDR 9%, FEV1 80% BDR 9%, FEV1 80% BDR 9%, FEV1 80% BDR 9%. B, Percent of patients in each
category deﬁned by baseline FEV1 80% and BDR 12% described by asthma diagnosis status and symptom severity. FEV1 80% BDR 12%,
FEV1 80% BDR 12%, FEV1 80% BDR 12%, FEV1 80% BDR 12%.
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20,21 and with conventional spirom-
etry,
10,22-24 even when baseline values were in the reference
range.
22,24
However, the major usefulness of the BDR in clinical
practice requires a cutoff point that best distinguishes children
with asthma from children without asthma. This has previ-
ously been estimated by epidemiological data in healthy chil-
dren
25 and by evaluating variability limits on repeated mea-
surements of baseline FEV1.
26 The Dales study found the
9% cutoff point included the 95th percentile conﬁdence
limits of healthy children, aged 9 to 11 years.
25 Strachan
reported that the 95th percentile for variability of FEV1
within the same day and between days in children 7 years old
was 10.2%.
26 The most direct approach, however, was taken
by Dundas et al, who, in the only earlier report we could ﬁnd,
compared several BDR cutoff points in healthy children and
children suspected to have mild, step 1 asthma assessed clin-
ically by a physician.
10 Similar to our ﬁnding, a BDR of
9% gave a better sum of sensitivity and speciﬁcity, 50% and
86%, respectively, than 12%, which had a sensitivity rate of
35% and a speciﬁcity rate of 98%. In our step 1 asthmatics (MI),
the sensitivity rate was 37% at the 9% cutoff point, perhaps
because we used 180 mcg, which is a frequently used dose in
children,
11 compared with 400mcg in the other study. Dundas
also observed that baseline FEV1, although reduced, was neither
sensitive nor speciﬁc in identifying the child with asthma.
10
Perhaps the major value of the BDR for the clinician
was shown in those with step 1 MI BA on the basis of
symptom frequency criteria (Figure 2A,B). By using combi-
nation criteria of FEV1 80%, BDR 9%, or both, we found
that 44.4% of the children classiﬁed as having MI BA had
abnormal spirometry results and thus could be candidates for
controller therapy. Although guidelines currently do not rec-
ommend controller therapy for MI BA, we recently reported
that 24.3% of those classiﬁed as having MI BA had signiﬁcant
exacerbations resulting in hospitalization or emergency out-
patient visits in the previous year.
27 Robertson et al found that
as many children with clinical evidence of mild BA die as
those who have more serious disease.
28 Furthermore, children
with mild disease experience far less morbidity when appro-
priately treated.
29
For diagnosis, a stepwise algorithm has been suggested
in children characterized by a careful history of chronic cough,
recurrent wheezing, and dyspnea relieved by bronchodilator
and exclusion of alternative diagnosis.
30 To conﬁrm the diagno-
sis, an objective test of airway obstruction is recommended.
1,30
Furthermore, when obstruction is demonstrated, a BDR
12% is suggested as more deﬁnitive evidence of BA diag-
nosis.
1,15,30 We would argue that these spirometric assump-
tions may not be valid in the pediatric population. First, as
seen in our data (Table II), most children have baseline FEV1
in the reference range (80%), with approximately 10% to
20% of children having levels 80% regardless of severity.
7
We found that a BDR 9% or 12% can be present even
with a baseline 80% (Figure 2A,B). In addition, a 9%
BDR increases sensitivity by 35% overall and by 68.5% in
those with MI disease in which sensitivity is needed most;
44.4% of the MI group would have been under-treated if we
assume that children with abnormal spirometry results should
receive controller medications even if BA is clinically mild. To
substantiate this assumption, several investigators have shown
that patients with a low FEV1 in childhood often continue to
have more severe airway obstruction in adulthood
31 and have
an increased morbidity rate.
32 In addition, an increased BDR
has been shown to be associated with biomarkers of inﬂam-
mation including exhaled nitric oxide
11-13 and bronchial eo-
sinophilia.
14 Furthermore, the BDR is a predictor of future
lung function
33 and correlates signiﬁcantly with responsive-
ness to inhaled corticosteroids.
14,34 We have demonstrated
that spirometry including the BDR can be successfully per-
formed in most children 6 years of age. Although in many
primary care settings the peak expiratory ﬂow is used in place of
spirometry to assess pulmonary function, it has been shown to
correlate poorly with the FEV1
6 and, therefore, it can be mis-
leading in evaluating the child suspected of having BA.
Several limitations need to be addressed in this obser-
vational, retrospective study. Our pediatric population was
predominantly Hispanic, from the inner city with poor access
to medical care. Although we did not ﬁnd any signiﬁcant
spirometric differences on the basis of ethnicity, one cannot
necessarily generalize our ﬁndings to other populations. Fur-
thermore, our non-asthmatic population did not consist of
“normal” prescreened healthy control subjects because they
were referred, usually by the school nurse on the basis of
perceived respiratory problems. Approximately 8% had a
FEV1 80%, and approximately 14% had a positive BDR
9%. In addition, we found that approximately 33% of sub-
jects were atopic on the basis of positive skin test results (data
not shown). The atopic state itself has been associated with an
increased BDR.
35 One would expect that the differences
between patients in whom BA is diagnosed and prescreened
healthy non-atopic subjects might be even greater than re-
ported here. Our cohorts might better reﬂect the “real world”
situation faced by the clinician in practice, where the asth-
matic child must be differentiated from a population of chil-
dren with a variety of respiratory symptoms, not healthy
children with no symptoms. We also did not account for
albuterol use 4 to 6 hours before spirometry. None of the
subjects had received long-acting beta agonists. However,
those reporting albuterol use 3 times per week had lower
baseline FEV1 (P  .014) and greater BDR (P  .001; data
not shown). One could assume that our results would have
been even better had we excluded children receiving albuterol
4 to 6 hours before spirometry. Patients were also not ex-
cluded on the basis of earlier upper respiratory infection
within 2 weeks of spirometry. However, this would apply to
both patients diagnosed with BA and the non-BA popula-
tion. The standard we used to determine the value of spirom-
etry was the diagnosis by the asthma specialist on the basis of
recommended guideline clinical criteria alone,
1 which has
frequently been the standard against which more objective
tests have been evaluated.
10,13
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although objective, provides only modest sensitivity in con-
ﬁrming the diagnosis of BA. Of greater potential is our
observation that the BDR in combination with baseline
FEV1 can detect a population of children with asthma with
only mild clinical manifestations who might beneﬁt from
inhaled corticosteroid therapy. Although conﬁrmation is
needed, we suggest that a BDR 9% be considered a positive
response in children. We recommend that the BDR be per-
formed in all children 6 years old who are suspected of
having BA as a practical tool that may help the physician
decide which therapeutic strategy is most appropriate.
Thanks to Joseph Spahn, MD, and Leonard Bacharier, MD, for
their advice on this manuscript, and to Rhonda Robles for manu-
script preparation.
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negative predictive value. The triangle denotes change.
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